Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart bracelet and app stop a second stroke?

NCT ID NCT07825311

Prevention Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether a digital program that combines a smart bracelet and a mobile app can help people who have had an ischemic stroke avoid another one. The study enrolls adults who recently had a stroke and also have high blood pressure and diabetes. Half receive usual stroke prevention care, and half receive usual care plus the 12-month digital program with reminders, health tips, and activity tracking. The trial measures whether the digital group has fewer recurrent strokes and better control of blood pressure, blood sugar, and cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a digital prevention program using a smart bracelet and mobile app
What this could lead to
If the digital program works, it could offer a low-cost way to help stroke survivors avoid another stroke and manage their risk factors.
What could go wrong
People may not stick with wearing the bracelet or using the app, and the digital approach might not outperform standard care. The trial is not blinded, so expectations could influence results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,696 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Diagnosed with ischemic stroke within the past 3 months, confirmed by cranial CT or MRI. * Have both hypertension and diabetes as concurrent metabolic risk factors for stroke recurrence. * Possess basic communication skills and ability to understand the study content and provide written informed consent. * The participant or their primary caregiver is able to use a smart wearable device, has access to a smartphone, and is willing to complete follow-up visits as required by the study protocol. Exclusion Criteria: * Life expectancy less than 12 months, or presence of severe cardiac, hepatic, renal, or other systemic diseases that would make participation in follow-up inappropriate. * Severe cognitive impairment, aphasia, psychiatric disorders, or disturbance of consciousness that prevents cooperation with the study, without a stable caregiver to assist. * Severe physical disability or other reasons that preclude wearing or using the wearable device. * Currently participating in another interventional study that may affect stroke recurrence outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digital health are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digital health Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.